FDAnews
www.fdanews.com/articles/87036-immtech-receives-expanded-funding-commitment-to-develop-pafuramidine-maleate

IMMTECH RECEIVES EXPANDED FUNDING COMMITMENT TO DEVELOP PAFURAMIDINE MALEATE

May 23, 2006

Immtech Pharmaceuticals, Inc. announced today that it has entered agreements with the University of North Carolina Chapel Hill (UNC-Chapel Hill) to provide expanded funding and support for Immtech's development of its oral drug candidate, pafuramidine maleate (DB289), to treat African sleeping sickness (trypanosomiasis). PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-23-2006/0004367171&EDATE=)